ImmuneOnco: IMM2520 invention patent was authorized by Japan Patent Office
On March 22, 2022, the bispecific antibody drug candidate (project number: IMM2520) independently developed by ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. that targets both CD47 and PD-L1 was authorized by the Japanese Patent Office (Japanese Patent Application number: JP2021-163660). IMM2520 proposal has also been submitted for patent applications in China, the United States, the European Union and other countries/regions. As one of the major pharmaceutical markets in the world, Japan took the lead in approving the patent authorization of IMM2520, which will greatly improve the market competitiveness of the project.
Dr. Wenzhi Tian, founder, chairman and CEO of ImmuneOnco, said:
"I am very pleased to see that our IMM2520 project invention patent has been authorized by the Japanese Patent Office. IMM2520 is an antibody-receptor recombinant protein (mAb-Trap) that targets both CD47 and PD-L1. The project is currently undergoing preparation of clinical trials in China. The research is progressing well, and we are confident to the future success of the IMM2520."
"We will further accelerate the research and development of the IMM2520 project, and strive to enter the clinical trial stage as soon as possible to benefit cancer patients."
IMM2520 is a bispecific antibody against both targets of CD47 and PD-L1 developed using ImmuneOnco’s mAb-Trap technology platform. IMM2520 binds to CD47 and PD-L1 on the tumor cell membrane simultaneously, blocking the signaling pathways of SIRPα/CD47 and PD1/PD-L1, thereby inhibits the immunosuppression of tumor cells on macrophages and T cells. Through genetic engineering of Fc fragments binding to Fcγ receptors, it also induces antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). In SIRPα and PD-1 double transgenic BALB/c mice loaded with CD47 and PD-L1 expressing CT26 tumor cells, IMM2520 demonstrated the efficacy of strong anti-tumor activities.